News
Zacks Small Cap Research on MSN1d
MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…(NASDAQ:MTVA) announced positive results from the Phase 1 Part 2 multiple ascending dose (MAD) trial of DA-1726 in obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback